Pharmalicensing Logo - Go to Home page
Register or Sign in to Save this opportunity, or Send an Inquiry.
New, Innovative CNS Drug Sought At End of Phase III Trial Level
Leiras Takeda Pharmaceuticals Finland flag Finland
Abstract ID:
New innovative drug to be used in some CNS-areas, primarily to support a product indicated for schizophrenia
Send an Inquiry
RE:
Participants
You

New innovative drug to be used in some CNS-areas, primarily to support a product indicated for schizophrenia.

Type of Business Relationship Sought

The clinical trials should have been mainly performed and there shouldn´t be a need for Takeda to make co-funding or co-development for the project.

FEATURED
Last Updated Sep 2014
Technology Type
Phase of Development CLINICAL TRIALS
CORPORATION
Leiras Takeda Pharmaceuticals
Paciuksenkatu 21 (LEIRAS)
PO Box 1406
Helsinki , FINLAND FIN-00101
Finland
Opportunity Contact
Leiras Takeda Pharmaceuticals
+358 20 746 501
Visit Website